Navigation Links
Immune Design Grants Adjuvant License to MedImmune
Date:10/26/2010

SEATTLE, Oct. 26 /PRNewswire/ -- Immune Design Corp. (IDC), a privately held biotechnology company developing novel vaccines and immunotherapies for infectious disease and cancer, announced today that it has entered into a license and development agreement with MedImmune for the use and commercialization of IDC’s proprietary Glucopyranosyl Lipid Adjuvant (GLA) as a component in vaccines for select infectious diseases.

"We are pleased to enter into this license with MedImmune as one of the world's leading vaccine research-based pharmaceutical and healthcare companies," commented IDC Executive Chairman Dr. Bruce Carter.  "This relationship fits very well with IDC’s business model to advance the development of GLA and enable innovative vaccine products that we believe will provide significant benefit in areas of unmet need while maintaining our commitment to global access."

Under the terms of the license agreement, IDC grants MedImmune exclusive worldwide rights to research, develop, use, and commercialize the GLA adjuvant in vaccines for specific indications.  In return, IDC will receive an upfront licensing fee and potential development, regulatory and commercial milestones totaling $212M, in addition to royalty payments on sales of marketed products.  

GLA is a toll-like receptor 4 (TLR-4) agonist which IDC has advanced into early clinical stage development.  The small molecule adjuvant has several important features including a pure synthetic composition with straightforward manufacturing and long term stability, a rational design for optimal activation of human dendritic cells, compatibility with antigens in multiple formulations, and a well established safety profile.  

About Immune Design Corp.: Immune Design Corp. is a privately held biotechnology company based in Seattle, WA.  IDC brings together some of the world’s leaders in the field of molecular immunology to develop vaccine
'/>"/>

SOURCE Immune Design Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. AutoImmune Inc. Reports 2008 Second Quarter Financial Results
2. Peptimmune Presentation at Upcoming World Congress on Treatment and Research in Multiple Sclerosis
3. EUPROBIO 2008 Presentation to Highlight Latest Immune Research
4. MedImmune Presents Data at AAP National Conference & Exhibition Demonstrating Burden of RSV Disease
5. MedImmune Expands R&D Capacity with New Research Facility in Cambridge, U.K.
6. MedImmune Licenses Reverse Genetics Technology to Hungarys Omninvest for Use in Influenza Vaccine Development and Production
7. MedImmune Presents Data Highlighting its Progressive Inflammatory Disease Portfolio at the 72nd Annual Meeting of the American College of Rheumatology
8. Peptimmune Presentations at Upcoming Events
9. Protein-printing technique gives snapshots of immune system defense
10. Visualizing asthma-causing immune cells at work
11. AutoImmune Inc. Reports 2008 Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... -- Technology Applications International Corporation (the "Company" or "NUUU")(OTC BB: ... Inc. has signed an additional exclusive licensing agreement with ... Johnson Space Center in Houston , ... Charles J. Scimeca , NUUU,s ... latest, exclusive agreement with NASA. In addition to our ...
(Date:9/2/2014)... , Sept. 2, 2014 Orexigen Therapeutics, ... the U.S. Patent and Trademark Office (PTO) has issued ... being evaluated for weight loss. NB32 is a fixed-dose ... U.S. Patent No. 8,815,889 claims methods for ... bupropion. The patent expires in 2024. If NB32 is ...
(Date:9/2/2014)... Md. , Sept. 2, 2014  Synthetic ... novel anti-infective biologic and drug candidates targeting specific ... today positive results from its final preclinical toxicology ... Administration (FDA) guidance, this bridging study was required ... candidate designed to prevent the devastating effects of ...
(Date:9/2/2014)... , Sept. 2, 2014  Spherix Incorporated (SPEX) -- an ... monetization of intellectual property, today announced that the United ... to the Company in the month of August that ... The issued patents are: ... U.S.RE45,081 issued August 19, 2014; and , U.S.RE45,095 ...
Breaking Biology Technology:Technology Applications International Corporation Subsidiary Enters Into Additional Exclusive Agreement with NASA at a Signing Ceremony at the Johnson Space Center In Houston, Texas 2Technology Applications International Corporation Subsidiary Enters Into Additional Exclusive Agreement with NASA at a Signing Ceremony at the Johnson Space Center In Houston, Texas 3Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 2Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 3Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 4Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 3Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 4Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 5United States Patent & Trademark Office Issues Three New Standard Essential Patents to Spherix 2
... 13 Proteon Therapeutics is,presenting new data ... potential of PRT-201 to enhance outcomes in ... (PAD). The,presentation, entitled, "Local Catheter-Directed Elastase Therapy: ... is being made at the 20th,annual Transcatheter ...
... CLARA, Calif., Oct. 13 WebLOQ, Inc., ... secure and compliant eBusiness and,data-in-motion communications, today ... the WebLOQ ePrivacy solution in their state-of-the-art,Monterey ... partner, the,Monterey Peninsula Surgery Center, and other ...
... SYDNEY, Australia, Oct. 13 /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis,Ltd (AXS: ... Quarterly,Report to Shareholders on the afternoon of Wednesday ... teleconference the following morning to,review the quarter and ... on Thursday 16th October at 8.30am (Sydney),(Wednesday 15th ...
Cached Biology Technology:Proteon Therapeutics to Present New Data on PRT-201 at Transcatheter Cardiovascular Therapeutics (TCT) Annual Symposium in Washington, D.C., October 13, 2008 2Monterey Spine and Joint Deploys WebLOQ ePrivacy Solution for HIPAA Compliant Health Information Exchange 2Monterey Spine and Joint Deploys WebLOQ ePrivacy Solution for HIPAA Compliant Health Information Exchange 3
(Date:9/2/2014)... may have discovered a new way of harnessing lupus ... DNA repair. , The findings were published recently in ... study, led by James E. Hansen, M.D., assistant professor ... that cancer cells with deficient DNA repair mechanisms (or ... significantly more vulnerable to attack by lupus antibodies. , ...
(Date:9/2/2014)... true that digital distribution of media will have ... at least when file sizes are large. , ... Yale,s Journal of Industrial Ecology that ... consoles such as PlayStation3. Researchers found that Blu-ray ... gas emissions than game files downloaded over broadband ...
(Date:9/2/2014)... 2, 2014 In a new study that could ... Florida campus of The Scripps Research Institute (TSRI) have ... unique manufacturing sites for molecules that can treat a ... as a reaction vessel and a disease-causing defect as ... cell," said TSRI Professor Matthew Disney.,"Because the treatment is ...
Breaking Biology News(10 mins):Sabotage as therapy: Aiming lupus antibodies at vulnerable cancer cells 2Scripps Florida scientists make diseased cells synthesize their own drug 2
... theoretical price of having one's personal genome sequenced just ... $2.2 million, and the goal is to reduce the ... realistic. , The sharp drop is due to a ... (HMS) researchers Jay Shendure, Gregory Porreca, George Church, and ...
... form of a powerful painkiller for a quick and dangerous ... alarm as the number of people dying from an overdose ... than morphine, rises. , Addicts are misusing a clear patch ... into the bloodstream over the course of a few days, ...
... with a Global Information System will provide valuable information ... National Institute of Environmental Health Sciences (NIEHS), one of ... provide the most up-to-date data to public health and ... industry maps, as well as demographic information for local ...
Cached Biology News:A step toward the $1,000 personal genome using readily available lab equipment 2Prescription pain patch abuse blamed for increase in deaths 2Prescription pain patch abuse blamed for increase in deaths 3FDA approves child-friendly AIDS medicine 2
... High-throughput protein crystallography involves using many ... Screening (HTS). The liquid handling requirements are ... volume: traditional crystallography plates have 24 or ... of microliters. For higher throughput, the number ...
... Description: ,Kit containing Dermal Fibroblasts (Mouse/BalbC) ... as a long-term culture, and is guaranteed ... continuous growth from the date supplied, when ... Dermis, mouse/BalbC, embryonic day 18.5 ,Applications: ...
... designed for protein pull-down experiments ... binding proteins. An order of ... agarose beads with 10 nmol ... terminus of the alkyl chain; ...
Rabbit polyclonal to Staphylococcus Enterotoxin A (HRP) ( Abpromise for all tested applications)....
Biology Products: